Cargando…

Analysis of Costs Associated With Administration of Intravenous Single-Drug Therapies in Metastatic Breast Cancer in a U.S. Population

An estimated $8.1 billion (in 2004 dollars) is spent annually on total health care costs for the treatment of breast cancer in the United States. Breast cancer has traditionally been treated with intravenous (IV) cancer therapies that entail not only the drug acquisition cost, but additional costs o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruse, Gregory B., Amonkar, Mayur M., Smith, Gregory, Skonieczny, Dean C., Stavrakas, Spyros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438104/ https://www.ncbi.nlm.nih.gov/pubmed/19006441 http://dx.doi.org/10.18553/jmcp.2008.14.9.844

Ejemplares similares

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population
por: Duh, Mei Sheng, et al.
Publicado: (2013)

Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database
por: Caroff, Stanley N., et al.
Publicado: (2022)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
por: Zoon, K C
Publicado: (1999)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

U.S. Health Resources & Services Administration
por: Washko, Michelle M.
Publicado: (2022)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
por: Kuehn, Carrie M.
Publicado: (2019)

Economic Costs of Diabetes in the U.S. in 2012
Publicado: (2013)

Economic Costs of Diabetes in the U.S. in 2017
Publicado: (2018)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration
por: Sullivan, Helen W., et al.
Publicado: (2016)

Prion gene haplotypes of U.S. cattle
por: Clawson, Michael L, et al.
Publicado: (2006)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
por: Abulwerdi, Gelareh A., et al.
Publicado: (2023)

Summary and Frequency of Barriers to Adoption of CPOE in the U.S
por: Kruse, Clemens Scot, et al.
Publicado: (2015)

Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice
por: Blume, Steven W., et al.
Publicado: (2015)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration
por: Jones, Makoto M., et al.
Publicado: (2018)

ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research.
por: Tong, Weida, et al.
Publicado: (2003)

U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.
por: Gaylor, D W, et al.
Publicado: (1998)

The U.S. Food and Drug Administration Risk Assessment on Lead in Women’s and Children’s Vitamins Is Based on Outdated Assumptions
por: Miodovnik, Amir, et al.
Publicado: (2009)

Cost-effectiveness of workplace wellness to prevent cardiovascular events among U.S. firefighters
por: Patterson, P. Daniel, et al.
Publicado: (2016)

Obesity and Morbidity Risk in the U.S. Veteran
por: Betancourt, Jose A., et al.
Publicado: (2020)

Precipitating Circumstances of Suicide among Active Duty U.S. Army Personnel Versus U.S. Civilians, 2005–2010
por: Logan, Joseph E, et al.
Publicado: (2015)

U.S. Hospitals’ Administrative Expenses Increased Sharply During COVID-19
por: Wang, Yang, et al.
Publicado: (2023)

Projecting the Future Diabetes Population Size and Related Costs for the U.S.
por: Huang, Elbert S., et al.
Publicado: (2009)

Containing U.S. health care costs: What bullet to bite?
por: Jencks, Stephen F., et al.
Publicado: (1992)

The attributable annual health costs of U.S. occupational lead poisoning
por: Levin, Ronnie
Publicado: (2016)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

U.S. Food and Drug Administration-Certified Food Dyes as Organocatalysts in the Visible Light-Promoted Chlorination of Aromatics and Heteroaromatics
por: Rogers, David A., et al.
Publicado: (2020)

602. Intravenous Push Versus Intravenous Piggyback Administration of Cephalosporin Antibiotics: Impact on Safety, Workflow, and Cost
por: Lee, Ryan, et al.
Publicado: (2021)

Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
por: Trumbo, Henry, et al.
Publicado: (2020)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Sino-U.S. Decoupling: The Roles of U.S. Congress
por: Guo, Baogang
Publicado: (2021)

Influence of the Duration of Intravenous Drug Administration on Tumor Uptake
por: Fouliard, Sylvain, et al.
Publicado: (2013)

Closed-Loop Intravenous Drug Administration Using Photoplethysmography
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7ma070i8ps31nniivejdh99ucg